The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

J Thromb Haemost. 2008 Aug;6(8):1439-41. doi: 10.1111/j.1538-7836.2008.03050.x. Epub 2008 Jun 4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Genetic Variation*
  • Genotype
  • Humans
  • Pharmacogenetics
  • Platelet Aggregation Inhibitors / blood
  • Platelet Aggregation Inhibitors / pharmacokinetics*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Polymorphism, Genetic
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / blood
  • Ticlopidine / pharmacokinetics
  • Ticlopidine / pharmacology

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine